Overview

Price chart · mood · technical indicators

CRSP

Crispr Therapeutics AGstock Healthcare

Biotechnology

$53.5861.58%Current Market Mood:Neutral

Market Mood

Price Range (1Y)

$33.03$78.48

Current: $53.58

Market Comparison

vs Healthcare Sector & Biotechnology Industry

CRSP

+61.58%

1Y Performance

Fundamentals

Updated daily after market close

P/E ratio—Forward 23.36

EPS (TTM)$-6.470.0% YoY

Profit margin0.0%HEALTHCARE

Market cap$4.98BMid cap

Wall Street coverage

$82.59median target· current $57.06 (+44.7%)27 analysts

Via 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.

Valuation

Forward P/E: 23.36
PEG ratio: -0.21
P/B: 2.59
P/S (TTM): 1418.47
EV/EBITDA: 14.16

Profitability & growth

ROE (TTM): -30.2%
Operating margin: -17912.0%
Revenue growth YoY: -97.6%
Dividend yield: —
Beta: 1.74

Last earnings

Feb 17, 2026 · Estimate $-1.17 · Reported $-1.37

Analyst estimate. Actual results often differ.

Ratios are point-in-time. Historical metrics — no guarantees about what comes next.

News & Sentiment

50 articles · sorted by date

Page 1 of 3 · 50 total

Via 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.

About Crispr Therapeutics AG

Company profile

CRISPR Therapeutics AG, a gene editing company, focuses on the development of gene-based transformative drugs for serious human diseases. The company is headquartered in Zug, Switzerland.

Classification

Sector: Healthcare
Industry: Biotechnology
Exchange: NASDAQ
Country: USA
Currency: USD

Company profile

HQ: BAARERSTRASSE 14, ZUG, SWITZERLAND
Fiscal year end: December
Latest quarter: Dec 31, 2025

Market cap$4.98B

Shares outstanding$96.4M

52W high$78.48

52W low$33.03

Educational content · Not investment advice or recommendations

We're educators, not advisors. Your decisions are your own. Disclaimer

Overview

CRSP

Market Comparison

Fundamentals

Wall Street coverage

Valuation

Profitability & growth

News & Sentiment

CRISPR Therapeutics AG 1Q 2026: Revenue $1.458M, EPS $(1.28) — 10-Q Summary

Earnings Flash (CRSP) CRISPR Therapeutics AG Reports Q1 Revenue $1.5M, vs. FactSet Est of $6.1M

CASGEVY revenue and cash build at CRISPR Therapeutics (NASDAQ: CRSP) in Q1 2026

CRISPR Therapeutics Provides Business Update and Reports First Quarter 2026 Financial Results

CRISPR Therapeutics (CRSP) Projected to Post Quarterly Earnings on Monday

Pictet Asset Management Holding SA Sells 25,129 Shares of CRISPR Therapeutics AG $CRSP

Assessing CRISPR Therapeutics (CRSP) Valuation After Casgevy Approval And CAR T Pipeline Progress

Is Early Casgevy Momentum Reframing CRISPR Therapeutics' (CRSP) Long-Term Profitability Narrative?

Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (LLY) and Crispr Therapeutics AG (CRSP)

UBS Group AG Boosts Stock Position in CRISPR Therapeutics AG $CRSP

CRISPR Therapeutics AG (CRSP) Dips More Than Broader Market: What You Should Know

ARK, Catherine Wood disclose 11.79% stake in CRSP (CRSP)

Why the market dipped but CRISPR Therapeutics AG (CRSP) gained today

CRISPR Therapeutics AG (CRSP) dips more than broader market: What you should know

CRISPR Therapeutics AG (CRSP) Dips More Than Broader Market: What You Should Know

CRISPR Therapeutics AG (CRSP) dips more than broader market: What you should know

CRSP Stock Firms Up As ARK Support And Needham Event Draw Traders

Why Crispr Therapeutics Stock Is Surging Again

CRISPR Therapeutics AG (CRSP) Stock Drops Despite Market Gains: Important Facts to Note

CRISPR Therapeutics AG (CRSP) Stock Drops Despite Market Gains: Important Facts to Note

About Crispr Therapeutics AG

Classification

Company profile

CRSP

Market Comparison

CRSP Market Analysis

Overview

CRSP

Market Comparison

Fundamentals

Wall Street coverage

Valuation

Profitability & growth

News & Sentiment

CRISPR Therapeutics AG 1Q 2026: Revenue $1.458M, EPS $(1.28) — 10-Q Summary

Earnings Flash (CRSP) CRISPR Therapeutics AG Reports Q1 Revenue $1.5M, vs. FactSet Est of $6.1M

CASGEVY revenue and cash build at CRISPR Therapeutics (NASDAQ: CRSP) in Q1 2026

CRISPR Therapeutics Provides Business Update and Reports First Quarter 2026 Financial Results

CRISPR Therapeutics (CRSP) Projected to Post Quarterly Earnings on Monday

Pictet Asset Management Holding SA Sells 25,129 Shares of CRISPR Therapeutics AG $CRSP

Assessing CRISPR Therapeutics (CRSP) Valuation After Casgevy Approval And CAR T Pipeline Progress

Is Early Casgevy Momentum Reframing CRISPR Therapeutics' (CRSP) Long-Term Profitability Narrative?

Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (LLY) and Crispr Therapeutics AG (CRSP)

UBS Group AG Boosts Stock Position in CRISPR Therapeutics AG $CRSP

CRISPR Therapeutics AG (CRSP) Dips More Than Broader Market: What You Should Know

ARK, Catherine Wood disclose 11.79% stake in CRSP (CRSP)

Why the market dipped but CRISPR Therapeutics AG (CRSP) gained today

CRISPR Therapeutics AG (CRSP) dips more than broader market: What you should know

CRISPR Therapeutics AG (CRSP) Dips More Than Broader Market: What You Should Know

CRISPR Therapeutics AG (CRSP) dips more than broader market: What you should know

CRSP Stock Firms Up As ARK Support And Needham Event Draw Traders

Why Crispr Therapeutics Stock Is Surging Again

CRISPR Therapeutics AG (CRSP) Stock Drops Despite Market Gains: Important Facts to Note

CRISPR Therapeutics AG (CRSP) Stock Drops Despite Market Gains: Important Facts to Note

About Crispr Therapeutics AG

Classification

Company profile

CRSP

Market Comparison